Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The stock's fall snapped a five-day winning streak.

Moderna stock ( MRNA) fell over 9% on Wednesday, forfeiting most of its gains from Tuesday's session during a volatile week for the stock seen after the first reported bird flu death in the US, which ...

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

(NASDAQ:NVAX) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But that scarcely detracts from the really solid long term returns generated by the company ...

Vaccine stocks received a major and sudden boost on January 7, 2025. Here's why these companies are experiencing tailwinds in ...

Tuesday closed down -1.11%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.42% and the Nasdaq 100 Index ($IUXX) ...

Investors are weighing Nvidia's big AI plans and puzzling over Trump's tariff policy in the wait for fresh jobs data.

Investors are weighing Nvidia's big AI plans and puzzling over Trump's tariff policy in the wait for fresh jobs data.

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid ...

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...